AUG 30, 2016 08:00 AM PDT

Precise generation of desired human cell-types from embryonic stem cells

Speakers
  • Senior Research Fellow, Genome Institute of Singapore, Singapore
    Biography
      Lay Teng Ang is currently a Visiting Assistant Professor at Stanford University and a Senior Research Fellow at the Genome Institute of Singapore, A*STAR. She received her B.A. (Honours) in Bioengineering from the National University of Singapore and her Ph.D. from the University of Cambridge under an A*STAR Scholarship. Lay Teng has eleven years of research experience and dedicated the past nine years working with human embryonic stem cells (hESCs) and their differentiation towards endodermal and mesodermal cells. Her research has been supported by two ETPL Gap Funding Grants from A*STAR (as PI and co-PI, respectively) and has led to manuscripts in Cell and Cell Stem Cell (as corresponding author). She further led the commercialization effort to position her technology as a research kit, which is now sold worldwide by Thermo Fisher Scientific, Inc. Her ultimate goal is to develop new human cell types for use in regenerative medicine and drug toxicology testing.

    Abstract:

    My research program focuses on building the technology to generate diverse human cell-types for application in regenerative medicine and drug toxicology testing. While embryonic stem cells (ESCs) have the potential to generate thousands of distinct human cell-types, this vast array of lineage choices has made it difficult to efficiently differentiate ESCs towards any single desired fate. To more accurately guide ESC differentiation, we have delineated comprehensive roadmaps that describe how ESCs are diversified into a wide variety of endodermal and mesodermal cell-types. These roadmaps have enabled the successful generation of human liver cells and bone progenitors that can engraft in mouse models and respectively regenerate human liver tissue or bones in vivo; as such these ESC-derived tissue progenitors serve as potential sources of human cells for regenerative medicine or drug toxicology testing
     


    Show Resources
    You May Also Like
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 18, 2019 04:00 PM CEST
    C.E. CREDITS
    JUN 18, 2019 04:00 PM CEST
    DATE: June 18, 2019TIME: 7:00am PDT, 10:00 EDT, 4:00pm CET PSCs represent an important tool in a wide range of applications, including basic research, disease modeling, drug...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    OCT 31, 2019 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 31, 2019 09:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 31, 2019TIME: 9:00am PDT, 12:00pm EDT INTRODUCTION: A major limitation for the development of 3D engineered tissues is the absence of viable and perfusable...
    Loading Comments...
    Show Resources